Bruker Corporation (NASDAQ:BRKR) Receives Average Recommendation of “Hold” from Brokerages

Shares of Bruker Corporation (NASDAQ:BRKR) have been given a consensus recommendation of “Hold” by the fifteen ratings firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $50.3846.

A number of equities analysts have recently weighed in on BRKR shares. Wells Fargo & Company boosted their price objective on shares of Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Jefferies Financial Group set a $50.00 target price on shares of Bruker in a research report on Thursday, February 12th. The Goldman Sachs Group cut their price target on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a report on Friday, February 13th. TD Cowen reduced their price target on Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a research note on Friday, February 13th. Finally, Bank of America raised their price objective on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, December 15th.

Bruker Stock Down 4.6%

BRKR opened at $33.72 on Monday. The firm has a market cap of $5.13 billion, a P/E ratio of -224.80, a PEG ratio of 2.11 and a beta of 1.19. The business’s fifty day simple moving average is $40.06 and its 200 day simple moving average is $41.15. Bruker has a 52 week low of $28.53 and a 52 week high of $56.22. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The firm had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. During the same period in the previous year, the firm posted $0.76 EPS. The company’s revenue for the quarter was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts anticipate that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be given a dividend of $0.05 per share. The ex-dividend date is Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker’s dividend payout ratio is -133.33%.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $35.44, for a total value of $70,880.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at $4,552,019.92. The trade was a 1.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 11,000 shares of company stock valued at $554,280. 27.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Sector Gamma AS increased its holdings in shares of Bruker by 28.0% during the 3rd quarter. Sector Gamma AS now owns 250,909 shares of the medical research company’s stock worth $8,152,000 after buying an additional 54,939 shares during the last quarter. Becker Capital Management Inc. boosted its holdings in Bruker by 606.8% in the third quarter. Becker Capital Management Inc. now owns 301,155 shares of the medical research company’s stock valued at $9,800,000 after acquiring an additional 258,545 shares during the last quarter. DNB Asset Management AS boosted its holdings in Bruker by 40.5% in the third quarter. DNB Asset Management AS now owns 143,257 shares of the medical research company’s stock valued at $4,654,000 after acquiring an additional 41,289 shares during the last quarter. Aquatic Capital Management LLC grew its position in Bruker by 120.3% during the third quarter. Aquatic Capital Management LLC now owns 349,596 shares of the medical research company’s stock valued at $11,358,000 after acquiring an additional 190,883 shares during the period. Finally, M&G PLC grew its position in Bruker by 233.0% during the third quarter. M&G PLC now owns 1,096,226 shares of the medical research company’s stock valued at $35,079,000 after acquiring an additional 766,992 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.